Daniel Leung, MD, MSc

University of Utah
Division of Infectious Diseases
30 North 1900 East Rm 4C416
Salt Lake City, UT
United States 84132

Biographical Sketch: Dr. Leung is a physician-scientist in the Division of Infectious Diseases at the University of Utah. He sees patients on the Infectious Diseases consult service at the University of Utah Hospital and in the Travel Clinic. He also heads up a research laboratory focusing on the immunology of diarrheal diseases in developing countries as well as investigating gut dysfunction in returning travelers.

Dr. Leung is a graduate of the University of British Columbia (BSc '98, MSc '01) and the Wake Forest University School of Medicine (MD '05). He completed his residency in Internal Medicine at the University of Washington, and a fellowship in Infectious Diseases at Beth Israel Deaconess Medical Center of Harvard Medical School. From 2010 to 2014, Dr. Leung lived and worked in Dhaka, Bangladesh, where he performed research on immunology of diarrheal diseases, with a focus on cholera in children, as a joint research fellow of a collaboration between Massachusetts General Hospital / Harvard Medical School and the Centre for Vaccine Sciences at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b).

Dr. Leung's research is funded by grants from the National Institutes of Health, the Thrasher Research Fund, and the Burroughs Wellcome Fund / American Society of Tropical Medicine and Hygiene.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 02/17/2015 by Daniel Leung

Papers:
F.67 Mucosal Associated Invariant T (MAIT) Cells are Highly Activated in Duodenal Tissue of Humans with Vibrio cholerae Infection

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".